$TEM News
Last published 12h ago
- 12h agoTEMTempus to Present Six Abstracts Accepted at the 2026 Connective Tissue Oncology Society Annual MeetingBusiness WireCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that six abstracts (including three oral presentations) will be presented at the 2026 Connective Tissue Oncology Society (CTOS) Annual Meeting taking place November 18–21 in Seoul. At this year’s meeting, Tempus will present clinical research on rare mesenchymal tumors, highlighting how advances in molecular diagnosis and clas ...
- 1d agoTEMBlood Cancer United Launches REALworld: AML to Accelerate New Treatments for Children with Blood CancerPR NewswireBlood Cancer United® today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation...
- 2d agoTEMSOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling CancerPR NewswireSOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver...
- 1w agoTEMTempus Q3 2026 Financial Results Call - TEMPUS AI INCEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to Tempest Q3 2026 Financial Results Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please pre
- 1w agoTEMTempus AI, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoTEMTempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor ProfilingBusiness WireTempus AI, Inc. (NASDAQ:TEM) today announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification
- 2w agoTEMBMYTempus Expands Strategic Collaboration with Bristol Myers SquibbBusiness WireTempus AI, Inc. (NASDAQ:TEM, "Tempus")) today announced a multi-year agreement with Bristol Myers Squibb (NYSE:BMY, "BMS")), under which BMS will license multimodal oncology data from Tempus through 2031
- 2w agoBMYTEMPathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological ConditionsBusiness WireTempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to license the dataset under a five-year, $55 million agreement Pathos’s AI expertise and agentic
- 3w agoTEMTempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLCBusiness WireStudy to be presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images Tempus AI, Inc. (NASDAQ:TEM) today
- 3w agoTEMTempus to Report Third Quarter 2026 Financial Results on November 2Business WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S.
- 3w agoTEMAIRDFHWAIFIQV+1The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking ShapeGlobeNewswireNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases earlier to helping doctors
- 4w agoTEMAmbry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare DiseasesBusiness WireNew offering combines whole genome sequencing, RNA analysis and ongoing reanalysis to help address diagnostic challenges Ambry Genetics, a leader in clinical genomic testing and a wholly owned subsidiary of Tempus
- 1mo agoTEMTempus Announces Multi-Year Collaboration with Moderna and MerckBusiness WireCollaboration to Support Potential Commercialization of Intismeran Autogene Tempus (NASDAQ:TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene
- 1mo agoHYFTABCLLLYTWST+1AI Drug Discovery Forecasts Vary Widely as Sector Shifts to DeploymentPR NewswireTowards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound...
- 1mo agoTEMTempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026Business WireTempus AI, Inc. (NASDAQ:TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 in Madrid. At this
- 1mo agoTEMTempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral RegurgitationBusiness WireECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance
- 1mo agoTEMRXRXTempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation ModelBusiness WireTempus AI, Inc. (NASDAQ:TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). Additionally, the two companies have entered into a new agreement under which
- 1mo agoTEMMorgan Stanley 24th Annual Global Healthcare Conference - TEMPUS AI INCEarnings Call TranscriptsPerfect. I think we can get started. Callum Tishmarsh here from the Life Sciences team at Morgan Stanley. Welcome to Day 2 of the Global Healthcare Conference. Really pleased today to be joined by Eric Lefkoski, Tempest'
- 1mo agoTEMMorgan Stanley 24th Annual Global Healthcare Conference - TEMPUS AI INCEarnings Call TranscriptsPerfect. I think we can get started. Callum Tishmarsh here from the Life Sciences team at Morgan Stanley. Welcome to Day 2 of the Global Healthcare Conference. Really pleased today to be joined by Eric Lefkoski, Tempest'
- 2mo agoTEMTempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare InnovationBusiness WireThe Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes Tempus AI, Inc. (NASDAQ:TEM) today
- 2mo agoTEMTempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in CardiologyBusiness WireThe Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention Tempus AI, Inc. (NASDAQ:TEM)
- 2mo agoTEMTempus to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireTempus AI, Inc. (NASDAQ:TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30
- 2mo agoHYFTTEMSDGRTWST+1AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030PR NewswireEquity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it....
- 2mo agoTEMTempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGsBusiness WireECG-PH clearance adds pulmonary hypertension to Tempus’ FDA-cleared AI products for atrial fibrillation and low ejection fraction Tempus AI, Inc. (NASDAQ:TEM) today announced it has received 510(k) clearance from the
- 3mo agoHYFTTEMSDGRABCL+1AI Found an Influenza Target That Survives Viral MutationGlobeNewswireAUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and
- 3mo agoTEMTempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic ApplicationsBusiness WireTempus' multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis Tempus AI, Inc. (NASDAQ:TEM), a
- 3mo agoTEMSecond Quarter 2026 Financial Results Conference Call - TEMPUS AI INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. My name is Angela and I will be your conference operator today. At this time, I would like to welcome everyone to the Tempest AI Second Quarter 2026 Financial Results Conf
- 3mo agoTEMTempus Reports Second Quarter 2026 ResultsBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, 2026. "Q2 was another exceptional
- 3mo agoHYFTAMDRXRXABSI+2A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is HeadedPR NewswireAmerican News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the most closely watched...
- 3mo agoTEMTempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision MedicineBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneOme pharmacogenomics (PGx) testing solution,
- 3mo agoTEMTempus AI Company Update - TEMPUS AI INCEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. My name is Duncan, and I will be your conference operator for today. I would like to welcome you to Tempus AI Company Update. All lines have been placed on mute to prevent
- 3mo agoTEMPSNLTempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformBusiness WireAcquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across
- 3mo agoTEMTempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health ServiceBusiness WireFindings from the multi-center Articulate Pro study show Paige Prostate improves diagnostic consistency, accelerates turnaround times, and reduces laboratory workloads Tempus, a technology company leading the
- 4mo agoTEMTempus to Report Second Quarter 2026 Financial Results on July 30Business WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday,
- 4mo agoHYFTTEMABCLSDGR+1As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the DataPR NewswireUSA News Group, There is a growing consensus in artificial intelligence that the models themselves are becoming interchangeable, and that lasting...
- 4mo agoTEMTempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare CancersBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate
- 4mo agoHTFLBFLYTEMIRTC16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapPR NewswireEquity Insider News Commentary — Congenital heart disease is the most common birth defect in the world, and the population living with it is growing, ...
- 5mo agoTEMTempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart RhythmBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and
- 5mo agoTEMGenetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome TestingBusiness WireResearch highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses Ambry Genetics, a leader in clinical genomic testing, and a wholly owned
- 5mo agoTEMGoldman Sachs 47th Annual Global Healthcare Conference - TEMPUS AI INCEarnings Call TranscriptsGood afternoon, everyone. I'm Evie Kozlowski, the Life Science Tools and Diagnostics Analyst here at Goldman Sachs. I'm joined here with Eric Levkoski, the CEO of Tempest AI. Thank you. Thank you so much for being here.
- 5mo agoTEMTempus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare
- 5mo agoTEMTempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding MembersBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of
- 5mo agoTEMTempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xHBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a
- 5mo agoTEMTempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to
- 5mo agoTEMTempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research CommunityBusiness WireInaugural program provides unprecedented access to Tempus' library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical
- 5mo agoTEMTempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant
- 5mo agoTEMTempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in OncologyBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American
- 5mo agoTEMTempus AI Investor Day - TEMPUS AI INCEarnings Call TranscriptsWelcome everyone. Welcome to our inaugural Investor Day. Great to have you here in person and thanks to those who are joining us virtually today. Before we begin, just a quick reminder, today's presentation will include
- 5mo agoTEMTempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor PortfolioBusiness WireTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only
- 5mo agoTEMTempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across OncologyBusiness WireExpanded platform delivers patient insights across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of